Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Bone marrow dosimetry: Regional variability of marrow-localizing antibody

Journal Article · · Journal of Nuclear Medicine
OSTI ID:381001
; ;  [1]
  1. Memorial Sloan-Kettering Cancer Center, New York, NY (United States); and others

In radiolabeled antibody therapy, imaging and biopsy-based methods are used to estimate marrow activity concentration when the administered antibody localizes to the marrow. Absorbed dose estimates obtained using such measurements may be subject to large variability due to the potential for regional differences in marrow activity concentration. This variability was examined in ten patients with leukemia after administration of {sup 131}I-labeled HuM195 antibody. Regions of interest were drawn around the head and neck of the numerus and femur (both sides) and around lumbar vertebra 3 (L3) and 4 (L4) on a series of planar images collected at multiple times postadministration of the antibody. A single exponential fit to each attenuation-corrected, time-activity curve was obtained to estimate clearance half-life and the back-extrapolated percent injected activity. The activity concentration in the femoral head and neck (mean and s.d. = 0.04 {plus_minus} 0.02 %ID/g) was not significantly different than that measured in L3 and L4 (0.06 {plus_minus} 0.02% ID/g) but was significantly lower than the concentrations measure din the humeral head and neck regions (0.07 {plus_minus} 0.03 %ID/g, p {le} 0.05). Although half-life estimates differing by more than a factor of 2 were observed among different regions for individual patients, no systematic difference was observed in half-life between regions overall. S-factors were used for individual marrow regions to determine the mean absorbed dose to marrow in the femoral and humeral heads and the lumbar vertebrae (L3 and L4) which were 0.66 {plus_minus} 0.3, 1.0 {plus_minus} 0.3 and 2.2 {plus_minus} 0.5 mGy/MBq (2.4, 3.8 and 8.3 rad/mCi), respectively. A single value is generally quoted for the absorbed dose delivered to the red marrow following marrow-localizing radiolabeled antibody administration. These results suggest that the regional marrow dose may differ significantly from the mean. 32 refs., 5 figs., 1 tab.

OSTI ID:
381001
Journal Information:
Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: 4 Vol. 37; ISSN 0161-5505; ISSN JNMEAQ
Country of Publication:
United States
Language:
English

Similar Records

Clinical implementation of new region-specific S-values for marrow dosimetry: Dose distribution vs mean marrow dose in radioimmunotherapy of leukemia
Journal Article · Sun May 01 00:00:00 EDT 1994 · Journal of Nuclear Medicine · OSTI ID:197984

Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy
Journal Article · Tue Jan 31 23:00:00 EST 1995 · Clinical Nuclear Medicine · OSTI ID:381136

Response of femoral and vertebral colony-forming units to $sup 226$Ra internal contamination in mice
Journal Article · Sun Nov 30 23:00:00 EST 1975 · Radiat. Res., v. 64, no. 3, pp. 467-474 · OSTI ID:4087893